Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers
about
DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity.Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials.Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway.Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype.PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53.
P2860
Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Adapting a drug screening plat ...... tizers with genomic biomarkers
@en
type
label
Adapting a drug screening plat ...... tizers with genomic biomarkers
@en
prefLabel
Adapting a drug screening plat ...... tizers with genomic biomarkers
@en
P2093
P2860
P1476
Adapting a drug screening plat ...... tizers with genomic biomarkers
@en
P2093
Ashley M Kern
Beow Y Yeap
Cyril H Benes
Henning Willers
Jason A Efstathiou
Jeff Settleman
Kathryn D Held
P2860
P304
P356
10.1158/1541-7786.MCR-14-0570
P577
2015-02-09T00:00:00Z